Research programme: biodefence vaccines - Crucell/Naval Medical Research Center

Drug Profile

Research programme: biodefence vaccines - Crucell/Naval Medical Research Center

Alternative Names: Biodefense vaccines - Crucell/Naval Medical Research Center

Latest Information Update: 16 Jun 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell; Naval Medical Research Center
  • Developer Naval Medical Research Center
  • Class Anthrax vaccines; Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anthrax; Yersinia infections

Most Recent Events

  • 06 Mar 2008 Preclinical development is ongoing
  • 07 Aug 2007 Ichor Medical Systems partners with the Naval Medical Research Center to assess Ichor's TriGrid™ Delivery System in the development of a DNA vaccine for anthrax and plague
  • 01 Sep 2005 Preclinical trials in Anthrax in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top